SeHCAT is a synthetic bile acid. After administration, it passes through the enterohepatic circulation as endogenous bile acids¹.
SeHCAT is indicated for the investigation of bile acid malabsorption and measurement of bile acid pool loss. It may be used in the assessment of ileal function, in the investigation of inflammatory bowel disease and chronic diarrhoea and in the study of enterohepatic circulation¹.
SeHCAT offers a relatively low radiation dose to the patient (0.26mSv), compared to a typical upper gastrointestinal CT exam(6.0mSv)^1,2.
It is supplied as capsules of 370kBq at the activity reference date. Each capsule is one patient dose and contains less than 0.1mg of tauroselcholic acid¹.
Selenium-75 has a physical half-life of approximately 118 days and decays by gamma emission with principal energies at 0.136 MeV and 0.265MeV¹.

References 2:

1) SeHCAT Summary of Product Characteristics, 2021.

2) What are the Radiation Risks from CT? | FDA US FDA website. Last accessed August 4th 2021.

3) Wedlake L et al. Aliment Pharmacol Ther 2009; 30:707–717.

4) Mottacki et al. Aliment Pharmacol Ther 2016; 43:884–898.

5) Smith MJ et al. J R Coll Physicians Lond 2000; 34:448– 451.

6) Kumar L et al. Gut 2013; 62:A284.

7) Borghede MK et al. Eur J Internal Med 2011;22:e137–e140.

8) Merrick MV et al. Br Med J (Clin Res Ed) 1985; 290:665–668.

Learn more about Bile Acid Diarrhoea

Diagnosing Bile Acid Diarrhoea with SeHCAT